

QUICK REFERENCE GUIDELINE FOR AMBULATORY TREATMENT OF URINARY TRACT INFECTIONS IN ADULTS

When to Order a Urinalysis (UA) and Urine Culture (UCx): Asymptomatic bacteriuria (ASB) is often treated unnecessarily, accounting for a substantial burden of unnecessary antimicrobial use. National guidelines recommend against testing for ASB, except in select circumstances¹. In the absence of signs or symptoms (see below) attributable to a urinary tract infection (UTI), patients with a positive UCx and/or pyuria on UA should not be treated with antibiotics irrespective of high bacterial colony count, or a multi-drug resistant organism. Therefore urine testing should only be obtained for appropriate reasons. A negative UA makes a UTI very unlikely to be the cause of the patient's symptoms, but a positive UA does not diagnose a UTI. Urinary symptoms are needed to diagnose a UTI. The following is an effective strategy for how and when to order a UA and/or UCx.



- ^a Exceptions to this recommendation include patients that are pregnant or undergoing a urologic procedure. Clinical judgement should be used for patients with baseline cogntive/functional impairment presenting with new functional decline or falls with systemic signs of potenital infection (i.e., leukocytosis) and without an alternative etiology. Rule out the possibility of a sexually transmitted infection or vaginitis.
- ^b These ambulatory guidelines do not apply to severe sepsis, or patients with more severe presentations of illness, including hypotension, or ≥ 2 SIRS criteria (SIRS Criteria: Heart rate > 90 bpm, respiratory rate > 20 breaths per minute, temperature < 36°C (96.8°F), white blood count < 4,000 cells/mm³, temperature > 38°C (100.4°F), white blood count > 12,000 cells/mm³).
- ^c In healthy women with classic signs and symptoms of a UTI, urine testing (UA or UCx) are not necessary, and the patient may be treated empirically. However, patients at risk for drug-resistant bacteria, patients with underlying health conditions putting them at risk for more serious illness, if suspicion for upper tract UTI is present (fever, flank pain), or patients with recurrent UTIs should have a UA and UCx sent. In addition, a negative UCx does not rule out a UTI in a patient with classic symptoms. Use clinical judgement and patient response to determine if antibiotics should be continued.
- ^d A UCx will only be performed if a UA result indicates an inflammatory response, and therefore possible infection. Notable UA results include: detectable nitrites, leukocyte esterase, and bacteria. This progression is a strategy to decrease unnecessary antibiotic treatment in samples indicative of colonization and not infection.²



Table of Contents

Table of Contents			
Asymptomatic Bacteriuria	Uncomplicated Lower Tract UTI (Cystitis)	Complicated Lower Tract UTI (Cystitis)	
Uncomplicated Pyelonephritis	Complicated Pyelonephritis	<u>Prostatitis</u>	

ical prophylaxis guidelines provide recommendations on microbial prophylaxis prior to genitourinary operation lable evidence does not support screening for, and tment of, asymptomatic bacteriuria prior to implantation osthetic orthopedic ³ , cardiac devices, or neurosurgical
ical prophylaxis guidelines provide recommendations on microbial prophylaxis prior to genitourinary operation lable evidence does not support screening for, and tment of, asymptomatic bacteriuria prior to implantation osthetic orthopedic ³ , cardiac devices, or neurosurgical
ical prophylaxis guidelines provide recommendations on microbial prophylaxis prior to genitourinary operation lable evidence does not support screening for, and tment of, asymptomatic bacteriuria prior to implantation rosthetic orthopedic ³ , cardiac devices, or neurosurgical
edures/devices. nancy: Urine culture should be sent and treatment adjusted based on susceptibilities. Follow-up urine cultures should be obtained for test of cure. <u>Contraindicated throughout pregnancy</u> : • Fluoroquinolones and doxycycline <u>Avoid in first 8 weeks of pregnancy</u> : • TMP-SMX
B



Clinical Setting	Empiric Therapy (Should take recent previous cultures	Duration	Comments
	into account)		
Uncomplicated Lower Tract Urinary Tract Infection (Cystitis) ⁴ (Non-pregnant female without obstruction, catheters, or co-morbid conditions except well-controlled diabetes mellitus)	<u>Preferred:</u> Nitrofurantoin 100 mg PO BID (contraindicated if CrCl < 30 mL/min)** <u>1st alternatives:</u> TMP-SMX* 1 DS tab PO BID 2 nd alternative: Fosfomycin 3 g PO x1 dose (consider cost) OR	Nitrofurantoin: 5 days TMP-SMX: 3 days Ciprofloxacin / levofloxacin: 3 days Fosfomycin: 1 dose	 Fosfomycin is less effective than nitrofurantoin and should only be used if a contraindication to nitrofurantoin exists Fosfomycin should only be used for <i>E. coli</i> or <i>Enterococcus faecalis</i>. It may be considered on a case-by-case basis depending on the severity of symptoms, allergies, resistance profile, and remaining oral options Fluoroquinolones are not recommended as 1st-line agents due to high rates of <i>E. coli</i> resistance and propensity for collateral damage (resistance, <i>C. difficile</i> infection)^{4,5,6}. Use should be reserved when other options are not feasible
	Cephalexin [®] 500 mg PO BID	Cenhalexin [.]	
	3 rd alternative: Ciprofloxacin* 750 mg PO BID OR Levofloxacin* 750 mg PO daily *Adjust dose based on renal function	7 days	 Pregnancy: Urine culture should be sent and treatment adjusted based on susceptibilities. Follow-up urine cultures should be obtained for test of cure. <u>Contraindicated throughout pregnancy</u>: Fluoroquinolones and doxycycline <u>Avoid in first 8 weeks of pregnancy</u>:
	 **The Beers Criteria recommends avoiding use in geriatric patients > 65 years with a CrCl < 30 mL/min 		■ TMP-SMX



Т

Т

Complicated Lower Urinary Tract Infection (Cystitis) ⁵ (Male, urinary catheter present or removal within the last 48 hrs, recent GU instrumentation, anatomic abnormality or obstruction, pregnancy or other significant co-morbid conditions such as uncontrolled diabetes or immunosuppression)	Preferred: Nitrofurantoin 100 mg PO BID (contraindicated if CrCl < 30 mL/min)** 1st alternatives: TMP-SMX* 1 DS tab PO BID 2nd alternative: Fosfomycin 3 g PO x1 dose (consider cost) OR Cephalexin* 1000 mg PO TID 3rd alternative: Ciprofloxacin 750 mg PO BID OR Levofloxacin 750 mg PO daily *Adjust dose based on renal function **The Beers Criteria recommends avoiding use in geriatric patients > 65 years with a CrCl < 30 mL/min	7 days (1 dose for fosfomycin)	 Empiric therapy should take prior antimicrobial susceptibility into account Recommend urinalysis with urine culture before treatment Nitrofurantoin and fosfomycin should be avoided if pyelonephritis is suspected (see Pyelonephritis) Fosfomycin is less effective than nitrofurantoin and should only be used if a contraindication to nitrofurantoin exists Fosfomycin should only be used to treat <i>E. coli</i> or <i>Enterococcus faecalis</i> and can be considered on a case-by-case basis depending on the severity of symptoms, allergies, resistance profile, and remaining oral options Remove urinary catheter whenever possible Antimicrobial choice should be adjusted based on urine culture and susceptibility testing Fluoroquinolones are not recommended as 1st-line agents due to high rates of <i>E. coli</i> resistance and propensity for collateral damage (resistance, <i>C. difficile</i> infection)^{4,5,6}. Use should be reserved when other options are not feasible Pregnancy: Urine culture should be sent and treatment adjusted based on susceptibilities. Follow-up urine cultures should be obtained for test of cure. Follow empiric therapy recommendations, but avoid the noted agents below. <u>Contraindicated throughout pregnancy:</u>
---	---	-----------------------------------	---



Clinical Setting	Empiric Therapy (Should take recent previous cultures	Duration		Comments
	into account)			
Uncomplicated Pyelonephritis ⁴ (healthy non-pregnant female with no indwelling device)	<u>Preferred:</u> TMP-SMX* 1 DS tab PO BID + Ceftriaxone 1 g IM x1 dose <u>Alternative:</u> Levofloxacin* 750 mg PO daily (or Ciprofloxacin 750 mg PO BID) + Ceftriaxone 1 g IM x 1 dose *Adjust dose based on renal function	TMP-SMX: 7-14 days (7 days can be appropriate for women <65 years with no comorbidities). May extend to 14 days if persistent symptoms	•	Urine culture and susceptibility testing should be obtained Fluoroquinolones may cause tendinopathy and tendon rupture especially among patients who are older (> 60 years), malnourished, and on oral glucocorticoids. They may also lead to potentially fatal arrhythmias in patients with QT interval prolongation, electrolyte abnormalities, clinically significant bradycardia, and in patients receiving antiarrhythmic medications.
		Levofloxacin / ciprofloxacin: 7 days	•	Consider admitting patients to be hospitalized if endorse persistently high fevers > 38.4°C, unable to maintain oral hydration or take oral medications, have a history of resistance to oral options, suspected urinary tract obstruction or concerns regarding patient adherence. Consider referral to infusion center for administration of initial IV/IM agent



Clinical Setting	Empiric Therapy	Duration	Comments
	(Should take recent previous cultures into account)		
Complicated Pyelonephritis (Male, urinary catheter present or removal within the last 48 hrs, recent GU instrumentation, anatomic abnormality or obstruction, pregnancy or other significant co-morbid conditions such as uncontrolled diabetes or immunosuppression)	Preferred: TMP-SMX* 1 DS tab PO BID + Ceftriaxone 1 g IM x1 dose Alternatives: Levofloxacin* 750 mg PO daily (or ciprofloxacin 750 mg PO BID) + Ceftriaxone 1 g IM x 1 dose *Adjust dose based on renal function	 7 days, IF meet the following criteria: Not neutropenic, HIV with CD4 < 200, or HCST/SOT been afebrile ≥ 48 hours (at day 7) No urinary diversion, recent urologic surgery, anatomic abnormalities, or relapsed infection Non-pregnant If the above criteria are not met: 14 days 	 Urine culture and susceptibility testing should be obtained Consider admitting patients to be hospitalized if endorse persistently high fevers 38.4C, unable to maintain oral hydration or take oral medications, have a history of resistance to oral options, suspected urinary tract obstruction or concerns regarding patient adherence Pregnancy: follow empiric therapy recommendations, but avoiding listed agents below <u>Contraindicated throughout pregnancy</u>: Fluoroquinolones and doxycycline <u>Avoid in first 8 weeks of pregnancy</u>:



Clinical Setting	Empiric Therapy (Should take recent previous cultures into account)	Duration	Comments
Prostatitis Patients typically present with frequency, urgency, urinary incontinence, poor stream, hesitancy, fever and a tender, edematous prostate on exam. Suspect prostatitis in men with relapse UTI with same pathogen.	<u>Preferred:</u> TMP-SMX* 1 DS tab PO BID OR Ciprofloxacin* 500 mg PO BID (or Levofloxacin 500 mg PO daily) <u>Alternative for patients with <i>E. coli</i> or <i>E. faecalis</i> in consultation with ID: Fosfomycin 3 g PO daily x1 week followed by 3 g PO q48h x6-12 weeks *Adjust dose based on renal function</u>	4-6 weeks	 Antimicrobial choice should be adjusted based on urine culture and susceptibility testing. Fluoroquinolones or TMP-SMX are preferred over beta-lactams due to better prostate penetration. Fluoroquinolones may cause tendinopathy and tendon rupture especially among patients who are older (>60 years), malnourished, and on oral glucocorticoids. They may also lead to potentially fatal arrhythmias in patients with QT interval prolongation, electrolyte abnormalities, clinically significant bradycardia, and in patients receiving antiarrhythmic medications. Insurance coverage and cost should be considered prior to prescribing fosfomycin especially in cases where extended duration is necessary.

*<u>Renal Dosing Recommendations</u>

**The Beers Criteria recommends avoiding use in geriatric patients > 65 years with a CrCl < 30 mL/min



REFERENCES:

- ¹ Nicolle LE, et al. Clinical Practice Guideline for the Management of Asymptomatic Bacteriuria: 2019 Update by the Infectious Diseases Society of America. <u>Clin Infect Dis 2019</u> <u>March 21.</u>
- ² Gandhi T, et al. Importance of urinary tract infection to antibiotic use among hospitalized patients. Infect Control Hosp Epidemiol 2009;30:193-5.
- ³ Sousa R, et al. Is Asymptomatic Bacteriuria a Risk Factor for Prosthetic Joint Infection? <u>Clin Infect Dis 2014;59:41-47.</u>
- ⁴ Gupta K, et al. International Clinical Practice Guidelines for the Treatment of Acute Uncomplicated Cystitis and Pyelonephritis in Women: A 2010 Update by the Infectious Diseases Society of America and the European Society for Microbiology and Infectious Diseases. <u>Clin Infect Dis. 2011 Mar 1;52(5):e103-20.</u>
- ⁵ Hooton TM, et al. Diagnosis, Prevention, and Treatment of Catheter- Associated Urinary Tract Infection in Adults: 2009 International Clinical Practice Guidelines from the Infectious Diseases Society of America. <u>Clin Infect Dis 2010;50:625-663.</u>
- ⁶ Harris PN, et al. β-lactam and β-lactamase inhibitor combinations in the treatment of extended-spectrum β-lactamase producing Enterobacteriaceae: time for a reappraisal in the era of few antibiotic options? Lancet Infect Dis 2015;15:475-485.
- ⁷ American Geriatric Society 2019, Updated Beers Criteria for Potentially Inappropriate Medication Use in Older Adults. J Am Geriatr Soc. 2019 Apr;67(4):674-694.

Authors: Lindsay Petty, MD Jerod Nagel, PharmD

Antimicrobial Subcommittee Approval: 12/2023	Originated: 06/2019	
P&T Approval: 01/2024	Last Revised: 11/2023	
Pavisian Uistany, Ambulatany Antihiatia Stawardshin Waskground OC/2010		

Revision History: Ambulatory Antibiotic Stewardship Workgroup: 06/2019

The recommendations in this guide are meant to serve as treatment guidelines for use at Michigan Medicine facilities. If you are an individual experiencing a medical emergency, call 911 immediately. These guidelines should not replace a provider's professional medical advice based on clinical judgment, or be used in lieu of an Infectious Diseases consultation when necessary. As a result of ongoing research, practice guidelines may from time to time change. The authors of these guidelines have made all attempts to ensure the accuracy based on current information, however, due to ongoing research, users of these guidelines are strongly encouraged to confirm the information contained within them through an independent source.

If obtained from a source other than med.umich.edu/asp, please visit the webpage for the most up-to-date document.